Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Szoke

Showing results (251-260 of 287) with videos related to

Pageof 29
Sort By:
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic LeukemiaJohn N Allan, Ian W Flinn, Tanya Siddiqi, et al.
Scientific Reports|March 16, 2021
Countrywide population movement monitoring using mobile devices generated (big) data during the COVID-19 crisisMiklos Szocska, Peter Pollner, Istvan Schiszler, et al.
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|September 19, 2022
3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohortO Godin, B Pignon, A Szoke, et al.
Journal of Immigrant and Minority Health|December 9, 2024
'We Need Equitable Exercise Opportunities': The Complexity of Leisure-Time Physical Activity and Its Relationship to Mental Health among Arab Canadians: The CAN-HEAL StudySarah Elshahat, Tina Moffat, Basit Kareem Iqbal, et al.
BMJ Open|June 3, 2024
Hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery (TRACTION): protocol for a phase IV randomised controlled trialBrett L Houston, Daniel I McIsaac, Rodney H Breau, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 25, 2019
Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohortG Fond, O Godin, M Dumontaud, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
Journal of Psychiatric Research|March 19, 2023
Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia - Data from the FACE-SZ cohortAndrei Szoke, Jean-Romain Richard, Guillaume Fond, et al.
Pageof 29

Showing results (251-260 of 287) with videos related to

Sort By:
Pageof 29
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic LeukemiaJohn N Allan, Ian W Flinn, Tanya Siddiqi, et al.
Scientific Reports|March 16, 2021
Countrywide population movement monitoring using mobile devices generated (big) data during the COVID-19 crisisMiklos Szocska, Peter Pollner, Istvan Schiszler, et al.
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|September 19, 2022
3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohortO Godin, B Pignon, A Szoke, et al.
Journal of Immigrant and Minority Health|December 9, 2024
'We Need Equitable Exercise Opportunities': The Complexity of Leisure-Time Physical Activity and Its Relationship to Mental Health among Arab Canadians: The CAN-HEAL StudySarah Elshahat, Tina Moffat, Basit Kareem Iqbal, et al.
BMJ Open|June 3, 2024
Hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery (TRACTION): protocol for a phase IV randomised controlled trialBrett L Houston, Daniel I McIsaac, Rodney H Breau, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 25, 2019
Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohortG Fond, O Godin, M Dumontaud, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
Journal of Psychiatric Research|March 19, 2023
Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia - Data from the FACE-SZ cohortAndrei Szoke, Jean-Romain Richard, Guillaume Fond, et al.
Pageof 29